Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESP301 for COPD or Bronchiectasis Exacerbations
NCT04858451Phase 2Terminated
- Sponsor
- Thirty Respiratory Limited
- Start
- Mar 2021
- Primary completion
- Dec 2022
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RESP301 in chronic obstructive pulmonary disease (COPD), bronchiectasis, sponsored by Thirty Respiratory Limited. Started Mar 2021; status: terminated.
02
Drugs
RESP301
03
Conditions
chronic obstructive pulmonary disease (COPD)bronchiectasis
Beyond the preview
Go deeper on NCT04858451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04858451.